What question did this study set out to answer?

This research aims to explore the role of C-type natriuretic peptide signaling in lung fibroblasts and its therapeutic implications for pulmonary fibrosis.

January 10, 2026Open Access

Pathophysiological and therapeutic implications of C-type natriuretic peptide/cyclic GMP signaling in pulmonary fibrosis

Resultado clave

A single injection of the long-acting CNP analog, MS~[Gln6,14]CNP-38, significantly reduced lung inflammation and fibrosis in a mouse model of pulmonary fibrosis.

Puntos clave

This research aims to explore the role of C-type natriuretic peptide signaling in lung fibroblasts and its therapeutic implications for pulmonary fibrosis.
Utilized cultured lung fibroblasts and precision-cut lung slices from patients with pulmonary fibrosis.
Studied mice with fibroblast-restricted knockout of guanylyl-cyclase-B.
Assessed effects of the long-acting CNP analog on lung inflammation and fibrosis.
Measured expression levels of proinflammatory and profibrotic cytokines.
Enhanced lung inflammation observed in fibroblast GC-B-KO mice after bleomycin treatment.
CNP signaling inhibition was linked to increased expression of profibrotic cytokines.
The long-acting CNP analog significantly reduced lung inflammation and fibrosis.

PICO estructurado

Does C-type natriuretic peptide (CNP) or its long-acting analog reduce lung inflammation and fibrosis in preclinical models?

Población

Cultured human lung fibroblasts (from IPF patients and controls), precision cut lung slices from PF patients, and mice with fibroblast-restricted knock-out of guanylyl-cyclase-B (GC-B) subjected to bleomycin-induced pulmonary fibrosis.

Intervención

C-type natriuretic peptide (CNP) in vitro, and a single subcutaneous injection of long-acting CNP analog MS~[Gln6,14]CNP-38 in vivo.

Comparador

Vehicle/saline treatment, and Cre-negative control littermates.

Resultado

Lung inflammation and fibrosis (assessed by BALF protein/cytokines, histology, and expression of profibrotic markers).surrogate

Endogenous CNP signaling in lung fibroblasts acts as a brake on inflammation and fibrosis, and pharmacological augmentation with long-acting CNP analogs represents a potential therapeutic strategy for pulmonary fibrosis.

Resultado numérico

Tasa de eventos absoluta: 0% vs 0%

Resumen

Activation of lung fibroblasts in response to epithelial injury and inflammation provokes pulmonary fibrosis (PF). Endogenous molecular brakes counteracting fibroblast activity can be targets for therapies. Preclinical studies of synthetic C-type natriuretic peptide (CNP) indicated that this hormone might provide such a brake. As shown here, CNP exerts antifibrotic effects in cultured lung fibroblasts as well as precision cut lung slices from patients with PF, supporting clinical relevance. Therefore, augmenting or supplementing endogenous CNP could improve the treatment of such patients. To unravel whether paracrine CNP counteracts inflammation-driven PF, we studied mice with fibroblast-restricted knock-out of guanylyl-cyclase-B (GC-B), its cGMP-synthesizing receptor. Fibroblast GC-B-KO mice had enhanced bleomycin-induced lung inflammation, with increased expression of proinflammatory, profibrotic cytokines. Nevertheless, subsequent PF was not exacerbated. Molecular studies revealed that inflammation led to inhibition of CNP signaling in resident myofibroblasts, namely GC-B downregulation and induction of CNP/cGMP-degrading pathways. Despite this, a single subcutaneous injection of the recently developed long-acting CNP analog, MS~Gln6,14CNP-38, abrogated experimental lung inflammation and fibrosis. We conclude that CNP signaling in lung fibroblasts has anti-inflammatory and antifibrotic effects. Attenuation of this endogenous brake participates in the pathogenesis of PF and rescuing this pathway with long-acting CNP-analogs may have therapeutic potential.

Me gusta

Guardar

Ver artículo completo